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Abstract
A vast portion of intellectual disability and autism spectrum disorders is genetically caused by mutations in chromatin
modulators. These proteins play key roles in development and are also highly expressed in the adult brain. Specifically, the
pivotal role of chromatin regulation in transcription has placed enhancers at the core of neurodevelopmental disorders
(NDDs) studies, ushering in the coining of the term enhanceropathies. The convergence of these disorders is multilayered,
spanning from molecular causes to pathophysiological traits, including extensive overlaps between enhanceropathies and
neurocristopathies. The reconstruction of epigenetic circuitries wiring development and underlying cognitive functions has
gone hand in hand with the development of tools that increase the sensitivity of identifying regulatory regions and linking
enhancers to their target genes. The available models, including loop extrusion and phase separation, have been bringing
into relief complementary aspects to interpret gene regulation datasets, reinforcing the idea that enhancers are not all the
same and that regulatory regions possess shades of enhancer-ness and promoter-ness. The current limits in enhancer
definition, within the emerging broader understanding of chromatin dynamics in time and space, are now on the verge of
being transformed by the possibility to interrogate developmentally relevant three-dimensional cellular models at
single-cell resolution. Here we discuss the contours of how these technological advances, as well as the epistemic
limitations they are set to overcome, may well usher in a change of paradigm for NDDs, moving the quest for convergence
from enhancers to the four-dimensional (4D) genome.
Introduction
Convergence and specificity in intellectual disability
and autism spectrum disorders
Neurodevelopmental disorders (NDDs) encompass a diverse
range of conditions that affect the lives of many individuals and
their families. Understanding their unfolding inmolecular detail
holds key to reduce such burden by enabling drug discovery
and/or repurposing approaches anchored both to a mechanistic
understanding and an elucidation of the most relevant levels
of phenotypic convergence. Specifically, intellectual disability
(ID) prevalence has recently been estimated between 0.05%
and 1.55% (1) and is associated to 3963 genes in the OMIM
database. The Simons Foundation Autism Research Initiative
(SFARI) lists 1089 genes and 2291 copy number variation (CNV)
loci associated to autism spectrumdisorder (ASD) within a range
of scores reflecting the strength of the causative evidence. These
numbers alone outline the complexity underlying the regulation
of cognition, sociality and their alterations. Such complexity in
the genetic architecture of ID andASD is compounded by the fact
that the acquisition of suchmutations is increasingly recognized
to occur de novo (mostly germline,with mosaicism detected thus
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far in a small percentage of individuals) (2). Moreover, while
mutations of each gene in the SFARI list are fully penetrant and
deemed causative mostly via haploinsufficiency, variations of
other genes are considered risk factors, and their combination
can lead to polygenic forms of such disorders (3) where each
gene contributes, thanks to its non-deterministic and rather
incomplete penetrance, toward ID and/or autistic spectrum
outcomes.
Despite the striking diversity of genetic causes identified
to date and the significant extent of phenotypic variation
notwithstanding, the major phenotypic and molecular com-
monalities shared across NDDs clearly warrant a systematic
effort in studying them jointly, starting from the most homoge-
nous subgroups, in order to elucidate the atlas of molecular
convergences onto which specificities will hopefully acquire
actionable relief (4). In fact, several shared, opposite or unique
phenotypes and endophenotypes, ranging from craniofacial
features to cardiovascular abnormalities, have been identified
across neurodevelopmental syndromes, including some in the
autism spectrum.
Among the most common genetic causes of ID and ASD are
mutations in chromatin regulators and transcription factors: 152
in the SFARI list, of which 97 enrich the gene ontology category
“positive regulation of gene expression” and 124 enrich “DNA-
templated regulation of transcription” (both with false discovery
rate < 2e−12 using Enrichr (5)). Mutations in genes that regulate
transcription, both affecting specific gene regulatory networks
and in a broader setting - such as the bulk deposition of a
histone mark, or chromatin organization - are likely to have an
immediate transcriptional impact, which reverberates through
effects that can dramatically impinge upon proper cell fate
acquisition or cell physiology. The majority of epigenetic mod-
ulators causing NDDs are highly expressed during a “window
of vulnerability” along the early phases of neuronal develop-
ment. Their expression in the fully developed central nervous
systems is mostly in the cortex, which contains neuronal cir-
cuits involved in higher cognitive functions such as language
processing, social awareness and visuospatial construction (6).
Still, the centrality of other regions of the brain in their mani-
festation, such as the hippocampus and cerebellum, cannot be
neglected (7–9). Furthermore, the concomitant presence in NDDs
of recurrent anomalies in neural crest-derived tissues, mainly
including peripheral nervous system, craniofacial, skeletal and
cardiovascular defects, has been revealing an increasing spec-
trum of comorbidity between the cognitive/behavioral features
that are hallmarks of NDDs and the neurocristopathies (10,11).
The enhancer-centric view of NDDs
Thus far, the most successful attempts at grounding con-
vergence are arguably reflected in the two categories of
synapthopathies and enhanceropathies. While the former
refers to NDDs sharing phenotypes that can be traced to
synaptic dysfunction, the latter has gained increasing traction
in recent years, encompassing disorders in which either
enhancer elements per se or, more usually, the genes involved
in the control of enhancer elements are mutated (12,13).
The physiopathological relevance of mutations in enhancer
elements for developmental abnormalities is already well
established (13), with prototypical examples found in the
mutations at the sonic hedgehog enhancer locus, which are
responsible for polydactyly, or in the long-range mutations
that affect globin expression in hemoglobinopathies (14,15).
More recently, brain-relevant enhancer activity in in vivomurine
reporter assays has been associated to the 5p14.1 region, which
is a significant locus of genome-wide association study hits of
ASD-associated variants, a claim that may well represent the
tip of the iceberg for analogous NDD-relevant findings across
neural specific enhancers. The pathogenic role of mutations
in regulators of enhancer function is instead already more
amply documented (6), including the example that we recently
characterized of Gabriele-deVries syndrome (16)which is caused
by haploinsufficiency of the YY1 protein that mediates looping
between enhancers and promoters (17,18).
Notwithstanding these advances, the fundamental challenge
for the notion of “enhanceropathies” in terms of illuminating
NDD convergence appears now to be twofold. Specifically,
it involves the very challenge of enhancer identification as
well as our evolving definition of their mode of actions, both
aspects that intersect our still emergent understanding of the
three-dimensional (3D) chromatin architecture, its dynamics,
cell specificity and pathogenic potential. Thus, it has been
proposed that the combination of the H3K4me1 and H3K27Ac
histone modifications suffices to identify active enhancers
(19), while H3K27Ac alone does not always suffice to call all
active enhancers (20). While H4K16ac is enriched together
with H3K27ac, globular modifications of H3, such as H3K64ac
and H3K122ac, have been proposed to more robustly identify
active enhancers, in comparison to H3K27ac (21,22). The
dynamicity of transcriptional enhancers remains however,
in this context, a salient and well recognized problem (22),
which eludes also the power of recent techniques derived from
chromatin conformation capture (3C), such as Hi-C, that instead
permit identification of topologically associated domains (TADs)
mediated by CCCTC-binding factor (CTCF) and cohesin (23),
largely conserved across cell types and even across species (24).
Indeed, the observation that the removal of CTCF and cohesin,
albeit impacting TAD structures, does not dramatically alter
global transcription has yielded a model in which TADs are
not responsible for general transcriptional regulation but play
a role in inducible gene expression driven by environmental
stimuli and/or developmental cues. This was confirmed through
the ablation of cohesin in macrophages and hematopoietic
stem and progenitor cells (HSPCs), which impaired their
capacity to activate inflammatory gene expression and HSPCs
differentiation following lipopolysaccharide treatment (25).
Such chromatin domains are mainly formed through two
main proposed mechanisms: i) the loop extrusion model, in
which DNA is actively extruded through a cohesin ring, until two
CTCF molecules respectively bound to CTCF convergent binding
sites are found (26,27), and ii) a phase separationmodel in which
BRD4 and proteins with intrinsically disordered regions interact
with each other inducing a phase separated region, in which the
local concentration of transcription factors ends up being higher
than that for the freely diffusing ones (28). The loop extrusion
model is mainly responsible for TAD formation and boundaries
between physically interacting regions found within chromo-
some compartments. Moreover, CTCF is also found inside TADs,
together with YY1, mediator, and cohesin, where it may con-
tribute to cell-specific enhancer–promoter interactions (29–31).
Indeed,mutations of mediator and cohesin proteins themselves
can lead to NDDs (32,33).
Several models of how enhancers exert their regulatory func-
tion have been proposed (24): the active ones are known to
be transcribed, independent of their distance from their target
genes. Among them, the closest ones (within the kb range) typi-
cally loop with target promoters,while a consensus on themode
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of activity of the farther ones is not known. In fact, they might
act solely by virtue of being transcribed into RNA molecules
which, in specific cases, have been observed to bind chromatin
regulatory complexes and mediate chromosomic structure rear-
rangements along distant interactions. Another mode of action
of distal enhancers is suggested by the fact that small RNAs,
upon binding, can modulate crucial chromatin regulators such
as the Creb-binding protein and polycomb repressive complex
2 (34,35). Still concerning distant enhancers, the possibility that
they might also act by attracting proteins responsible for intro-
ducing rigidities and steric hindrances impacting on the chro-
mosomal organization cannot be a priori excluded. Moreover,
when looping is schematized and graphically represented, the
double strand nature of DNA is often not considered, and the
effective binding mode of transcription factors and RNAPII is
often forgotten. To this end, computational work by Hegyi posits
the hypothesis that transient 4G quadruplets, formed through an
equal contribution of two 2G sequences by a couple of promoter
and enhancer binding as single strands,might play an important
role to transcriptional regulation (36).
Disease modeling, human-derived 3D cultures and
single-cell omics
In the last decade, the power of patient-derived induced
pluripotent stem cells (iPSCs), coupled with an expanding
range of differentiation paradigms, has enabled the attain-
ment of increasingly sophisticated in vitro recapitulations of
pathologically affected tissues (37). In the context of neuro-
degenerative and neuro-developmental disorders studies, this
fast-evolving field has moved from a more heterogeneous dual
SMAD inhibition protocol to the ability of quickly produc-
ing homogeneous cultures of adult cortical neurons (38,39).
A crucial further advancement has been posed by stem-
cell derived 3D human brain organoids (40). These models
have the ability to robustly recapitulate, in terms of cellular
composition and connectivity, the districts of the brain that
are mostly affected in each condition, both separately and
assembled (40).
Most cases of ID and ASD appear in a syndromic form,
and given their secondary traits, such as craniofacial features,
peripheral nervous system impairment and cardiovascular
defects, many of them can also be included under the rubric
of neurocristopathies. In fact, neural crest stem cells migrate in
the very early stages of development to populate and constitute
several districts of the body after several specific differentiation
stages (41–44). The advent of somatic cell reprogramming
(45,46) allows us now to ask fundamental questions regarding
shared and specific vulnerabilities of the neural crest during
development (47–50), with models of different types of neural
crest cells have recently become available (51).
Mutations of epigenetic factors that cause NDDs generally
come in the form of haploinsufficiencies, and knock-out of
the same genes in cell lines often results in lethality (6).
These disorders affect only certain organs and tissues, in a
dynamic and time-specific fashion. Single-cell RNA-seq has
further highlighted how certain mechanisms and conditions
can be highly cell-type specific (52,53). Moreover, individual
genetic backgrounds are strongly associated with enhancer
and chromosomal organization, as recently demonstrated by
a thorough characterization of human single nucleotide poly-
morphisms (54). This further supports the previous observation
that, to precisely identify and describe relevant transcriptional
differences in the human context, a substantial number of
biological replicates is required (55).
The genome-wide focus at the level of individual cells
has gained momentum and is catalyzing a technological
revolution that is rapidly extending such gaze beyond the
transcriptome to encompass several other omic layers (56). Such
technologies become fundamental in order to reconstruct the
epigenetic circuitries defining the convergences of NDDs. Even
recent techniques like HiC have advanced to the single-cell
domain (single-cell HiC), and their application has revealed a
foundational heterogeneity in chromosomal contacts defining
TADs (31,57–59) and highlighted how TAD structures can be
largely conserved across species and along evolution, above the
megabase scale, while while typically less conserved at smaller
levels. Nevertheless, HiC is a technique that does not allow
for a nucleosomic resolution, which has been made possible
only by micro-HiC, which employs micrococcal nuclease instead
of restriction enzymes, and it has been proposed to obtain a
resolution up to ∼100/200 nt (60).
NDDs converge beyond types of genetic lesions and
affected chromatin remodelers
By analyzing in a concerted way, along in vitro differentiation,
patient-derived iPSCs, carrying a diverse set of mutations that
cause developmental disorders with shared clinical manifesta-
tions, one could aim at identifying critical shared and exclusive
nodes of transcriptional (and later on functional) dysregulation
caused by mutations in chromatin modulators.
Among NDDs caused by mutations or CNVs affecting
chromatin regulators, we selected some for their partially
overlapping clinical manifestations as a template example
(Table 1). Activity Dependent Neuroprotector Homeobox (ADNP)
is mutated in Helsmoortel van der AA syndrome (HVDAS)
(ADNP-ASD or HVDAS), with a 0.17% estimated prevalence
of pathogenic variants in individuals diagnosed with ASD,
thus defining it as one of the most commonly mutated single
genes causing autism (61). Patients with mutations in this gene
also share characteristic faces with a high hairline, prominent
forehead, eversion or notch of the eyelid, broad nasal bridge,
and thin upper lip. BAZ1B and GTF2I are both located in
the Williams Beuren syndrome chromosome region (WBSCR),
spanning around 27 genes on chromosome 7. CNVs of this
region, which is flanked by highly repeated sequences, lead,
during chromosome crossing-over at meiosis, to a partial or
complete hemizygous deletion or duplication of the WBSCR,
causing Williams Beuren syndrome (WBS) (62–64) or 7q11.23
micro-duplication disorder (7DupASD), respectively (65,66). WBS
features broad forehead, bitemporal narrowing, wide mouth,
full lips, small jaw, and prominent earlobes. Usually, WBS
individuals also show small spaced teeth and Iris stellate,
which is a very common characteristic. In contrast to WBS,
7DupASD can be subtler in cranio-facial phenotypic terms and is
supposed to have been underdiagnosed (63,64,67). Nevertheless,
when spotted, 7DupASD patients’ facial features are usually
opposite to those of WBS patients. Intellectual abilities are only
partially impaired in both disorders in a symmetric way, with
WBS individuals showing hypersociability and good grammar
skills compared to individual with comparable overall ID, and
7DupASD showing social withdrawal and severe language
impairments. Additionally, EED, EZH2, and SUZ12 mutations
have been found to be causative ofWeaver syndrome (WS),while
KMT2D and KDM6A mutations cause Kabuki syndrome (KS). It
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Table 1. Neurodevelopmental disorders show shared and unique clinical features
Clinical Williams
Beuren
Syndrome
7q11.23
μDup
Cornelia De
Lange
Syndrome
Kabuki
Syndrome
Weaver
Syndrome
GADEVS ADNP ASD Summary
Intellectual
disability
+ + + + + + + ∗∗∗∗∗∗∗
Visuospatial
impairment
+ + + optical - - + ∗∗∗∗∗
ASD features rare + rare rare - - + ∗∗∗∗
Hypersociability + - - - - - - ∗∗
Craniofacial
dysmor-
phism
+ + + + + + + ∗∗∗∗∗∗
Cardiovascular
defects
+ + + + + rare + ∗∗∗∗∗∗
* = number of NDDs featuring the given clinical trait
is noteworthy that these two syndromes are respectively caused
by mutations in genes either implicated with transcription
silencing (Polycomb Repressive Complex 2) or enhancement
(COMPASS complex) and show several opposite traits, such
as tall vis a vis short stature and distinctive cranio-facial
features (68–73). WS features macrocephaly, tall stature and
micrognathia, with mild ID, while its facial features can include
a broad forehead, hypertelorism, large low-set ears and dimpled
chin. KS features long and narrow lid fissures, and the lateral
third of the lower lids are often everted. Eyebrows are highly
arched and broad with some sparsity, especially in the lateral
portion and thick eyelashes. Ptosis and strabismus are both
quite recurrent. Cleft lip and palate are seen in about a third
of patients, and the palate is highly arched in most of them.
Similarly to WBS, teeth are usually small and widely spaced, but
they can also be malformed. Cornelia de Lange syndrome (CdL)
is caused by mutations in cohesin subunits and partners such
as NIPBL, SMC1A, HDAC8, RAD21, and SMC3. Characteristics of
these disorders largely overlap with those of KS including small
stature, microcephaly, and small and widely spaced teeth (74).
Finally, YY1, as previously mentioned, is mutated in the
recently characterized Gabriele-De Vries syndrome (GADEVS)
(17), which features low-set ears and general fullness to the
periocular area. Alike WBS and KS patients, slant downward lid
fissures and strabismus are often present.
Among these disorders, CdL and GADEVS can serve as exem-
plary cases inwhich NDDs unmask a higher level of convergence
than “enhancer” regulation. In fact, these two disorders are
caused bymutations of genes involved in the regulation ofmech-
anisms that have been used in a complementary manner but
also alternatively to explain transcriptional regulation through
enhancers.Namely, by affecting cohesin subunits and its loading
effector, CdL is characterized by phenotypic manifestations that
are comparable to GADEVS ones, which instead is caused by
mutations of YY1. Cohesin is fundamental for loop extrusion
models, working in concert with CTCF, while YY1 is at the
base of enhancer–promoter association and has been involved
with super-enhancer states,which rely onmechanisms of phase
separation (28).
Discussion
The ontological rationale for grouping several NDDs under the
rubric of enhanceropathies has contributed to our understand-
ing of their pathogenic mechanism and has enabled relevant
first strides toward the elucidation of their convergence.Theuni-
fying traction of this notion is coming,however, under increasing
tension due to our rapidly evolving understanding of transcrip-
tional regulation and the multiple scales that such understand-
ing must confront.
First, the relevance of chromosomes’ 3D structure for the
regulation of gene expression is being dissected at accelerated
pace and ever-increasing resolution, triggering a fundamental
reassessment of the hierarchical relationship between this level
of organization and previously defined enhancer/promoter-
centered models. In this respect, cohesins have been shown
to be necessary for the formation of TADs, and they have been
identified as the main, albeit not the only, building blocks of
genome 3D organization. In fact, accumulating evidence shows
that the formation of chromosome territories — regions of
the nucleus where chromatin partitions are active and closely
regulated (75) — is independent of TADs. In turn, among
chromatin architects, CTCF and YY1 have been shown to
define, respectively: i) insulation and TADs boundaries, and ii)
looping of enhancers and promoters (Fig. 1A). The relationship
between these architectural features and the actual process
of transcription is itself however highly dynamic and appears
to be increasingly mutually constitutive. Thus, 1) chromatin
looping was found to be stabilized by active transcription
(76), 2) promoter–promoter interactions can also serve the
purpose of enhancing transcription, and 3) enhancers are
themselves transcribed, ushering in a rich tapestry of imbricated
regulatory controls recently condensed in the notion that
genomic locations can possess shades of “promoter-ness” and
“enhancer-ness” (77).
A case in point, in this ongoing reassessment of regulatory
hierarchies with the attending disentanglement of architectural
structures from functional readouts, is the current debate on
the overlap between the notion of “transcription factories”
and the more recent phase-separation-based models of
transcriptional control. Indeed, the concept of “transcription
factories” (78) largely predates the phase-separation model
that is currently on the rise and may serve to sharpen some
elements of the enhancer discourse. The two notions are in fact
clearly distinguishable, at least in their origins. “Transcription
factories” describe the basic mechanism of aggregation of the
transcriptional machinery around active genes, hence the
formation of nuclear compartments that include regulatory
elements, RNAPII, and eventually other complementary proteins
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Figure 1. Schematic representation of the main models of chromatin architecture. (A) The loop extrusion model requires two CTCF binding chromatin in opposite
orientation, blocking cohesin and fostering the formation of loops by extrusion through cohesin ring. YY1 is depicted binding enhancer–promoter connections. eRNAs
and mRNAs produced by the transcription of enhancers and gene body are depicted. (B) Regulatory hubs [drawing inspired by Sabari et al. (28)]. Small ones may or not
form condensates, while large have been observed. (C) Cohesin (orange) and CTCF (in purple) favor the formation of TADs and chromosomal territories. Inside these
macro-partitions, YY1 (in yellow) and other factors (in grey) determine active and inactive subcompartmentalization.
defining independent subnuclear compartments. The phase-
separation model identifies instead the specific situation in
which large and abundant regulatory regions are combined
with chromatin modulators possessing intrinsically disordered
tails (IDTs), favoring dynamic and highly specific protein
complexes formation. In order to form, such condensates
need thresholds of physicochemical requirements, such as the
concentration of certain histone marks and histone-binding
proteins themselves. We argue however that, although the
two concepts are originally distinct, in terms of both their
historical and epistemic roots, the basis of the process giving
rise to either the historically defined transcriptional factories
or the currently investigated phase-separated compartments,
is the same mechanism, namely, the capacity of bromodomain
proteins (BRD4 in primis) to recognize active enhancer marks,
such as H3K27ac. Once multiple BRD4 proteins (or the likes)
bind H3K27ac tails, they start to build multimeric clusters
(with the help of their Asn- and Pro-rich amino acidic residues
composition), further attracting IDT-featuring partners. Such
condensate would acquire physicochemical and biochemical
characteristics capable of enhancing the gathering of specific
chromatin and transcriptional modulators. This mechanism
might occur in small hubs of regulatory and coding regions,
without giving rise to detectable condensates, as well as in large
ones with full-fledged outcome (Fig. 1B). Such principles could
easily be applied also to poised and inactive regulatory regions,
where alternative histone modifications and chromatin binding
proteins could respectively favor the rapid access to “poised”
or “repressive” transcriptional machineries. In the latter case,
the sudden removal of active marks could ablate the presence of
active transcribers and their substitution by Polycomb repressive
complexes.
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A second challenge for the heuristics of the notion of
“enhanceropathies” comes from the challenge of identifying
enhancers by intersecting multiple analytical techniques,
only some of which currently permit to tackle the structural-
functional cross-talk we outlined above at relevant resolution.
Thus, on the one hand, the identification of enhancers still
requires the combination and validation through orthogonal
techniques such as classical genetics, biochemistry, super-
resolution imaging and genomics (24,79). However, precisely
because chromatin conformation capture and ChIP techniques
rely on cell collection and destruction, live imaging such
as super-resolution imaging and single-molecule tracking is
needed to study chromatin loops and enhancer–promoter
dynamics during development (76,80–82). On the other hand,
the more we deepen our gaze into the molecular details of the
hierarchies of transcriptional control, the more the problem of
enhancer identification evolves into a definition issue. In fact,
we arewitnessing the historicalmoment of convergence of three
crucial developments: the understanding of what enhancers
really are, the increasingly resolved molecular characterization
of transcriptional regulation, and finally the ongoing appreci-
ation of the multi-dimensional nature of the genome. Thus,
while the search for distal elements positively and temporally
affecting transcription (i.e. enhancers) has transformed the field
of developmental biology, the availability of single-cell resolved
tools and the realization that several NDDs converge, in terms
of their causative mutations, at a genome-architecture level
beyond the limits of enhancer definition, call for a paradigm
shift. Specifically, we propose that a contemporary roadmap for
understanding NDDs in a patient-tailored and actionable man-
ner should entail the following: i) increasing the resolution of our
molecular enquiries via single-cell and single-moleculemethods
in patient-specific, physiopathologically relevant 3D models
of brain development; ii) changing our focus, from “identified
enhancers” along with the specific mutated chromatin modu-
lators underlying each condition, to the derangements in chro-
matin architecture that accrues in thosemodels at themeaning-
ful developmental stages, thereby shifting up one layer our quest
for convergence; and iii) changing our theoretical framework
accordingly, not to replace the established working merits of the
notions of enhancer and enhanceropathies, but to embrace the
need of defining types of enhancers, and eventually new types of
regulatory regions, to realize a less enhancerocentric and more
structure-aware vision of genome regulation. We would thus
like to propose, taking cues from the knowledge available thus
far on NDDs, that the regulation underlying human cognition
at the level of chromatin and transcriptional regulation is
productively captured by the notion of the manifold, a multi-
dimensional object whose constituents can be projected in
an Euclidean space. The identification of local interactions
between genomic regions and proteins binding to them, along
with the reconstruction of their supramolecular structures, can
thus help define 3D epigenetic neighborhoods that build, along
development, our 4D genome. In this view, what enables the
deployment of our cognitive functions is thus the constant
and temporally fine-tuned cross-talk within and between
chromosomal territories and their subcompartments (Fig. 1C),
unfolding through neural development at the level of individual
cells in their mutual set of proximal and distal connections.
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